Although the immunosuppressive role of stem cells has been confirmed in various studies, more implications of these cells for the treatment of diseases require greater recognition of precise mechanisms beyond their functions. In this study, NLRC3 and NLRC5 gene expressions were examined in IFN-γ-treated WJ-MSCs. Due to their capacity for renewal and differentiation into other cell lines, WJ-MSCs have broad therapeutic potential for regenerative medicine and cell-based therapies. However, some problems (such as stimulating the recipient’s immune system) have always been a major stumbling block in this regard. As in 1985, the bone marrow stromal cell system was first described by Owen and Friedenstein in connective tissue engineering, cell transplantation, hematopoietic stem cell transplantation, and gene therapy. Their research results extensively demonstrated the osteogenesis potential in cultured cells from bone marrow (
25).
NLRs are a batch of PRRs expressed in non-immune cells (including epithelial, mesothelial, and immune cells), which play key roles in immunity and regulate antigen presentation (NLRC5 and class II major histocompatibility complex transactivator [CIITA]) of pathogens and/or damaged cells (NLRP1, NLRP3, and NRC4) to suppress or modulate inflammation (NLRC3, NLRP6, NLRP12, and NLR family member X1 [NLRX1]) (
26). Among the NLRC subfamily, studies have shown that NLRC1 (NOD1), NLRC2 (NOD2), and NLRC4 play important roles in the host defense against bacterial pathogens (
27,
28). NLRs are expressed in non-immune cells, including epithelial, mesothelial, and immune cells. Studies have shown that NLRs are also involved in multiple non-inflammatory roles, as NLRC1 and NLRC2 regulate the differentiation of human umbilical cord blood-derived MSCs (
29).
In this study, isolation of Wharton’s jelly stem cells from human umbilical cords of healthy newborns was performed using the tissue culture method, as described in previous studies (
30,
31). The Wharton’s jelly stem cells were observed on days 10 - 14. The relatively low number of cells was seen to form long and flattened colonies. This was in accordance with the findings of Gronthos and Simmons and Kuznetsov et al. (
32,
33). Then, these cells were rapidly proliferated over time, and the number of cells increased, which forced us to passage into the flasks (
19,
33).
Recent studies have identified NLRC5 as an immune regulator. NLRC5 regulates MHC class I gene expression and could be a potential target for transplant rejection and cancer immunotherapy (
34). NLRC5 has high levels of expression in immune cells, including macrophages derived from bone, splenic dendritic cells, CD4+ T cells, CD8+ T cells, and B cells (
15). Harton et al. showed CLR16.2 (a partial sequence from NLRC3) expression in a variety of human immune cell classes, especially in T cells, while its expression seems insignificant in epithelial cell lines (
35,
36). Conti et al. suggested that CLR16.2 plays a role in the reduction of T cell activation (
37), proposing its potential to efficiently modulate immune responses. Also, Schneider et al. displayed that NLRC3 inhibits TLR4-mediated NF-κB activation and inflammation (
17). Biswas et al. and Yao et al. found NLRC5 as an important regulator of MHC class I genes, promoting the host defense (
38,
39).
Our results showed that NLRC3 and NLRC5 genes were expressed at low levels in untreated WJ-MSCs cells (control), while IFN-γ–treated WJ-MSCs were highly enriched in their mRNA transcripts. The results are consistent with previous data, showing that NLRC5 mRNA and protein were strongly induced in the mouse macrophage cell line when the cells had been treated with lipopolysaccharide. Thus, it is concluded that NLRC5 might be a negative regulator of NF-κB and type I interferon signaling pathways, playing an important role in modulating innate immunity (
40). Meissner et al. reported that NLRC5 was rapidly induced when cells were exposed to IFN-γ, while induction of MHC class I molecules was occurred later (
41). In line with our study, Kuenzel et al. reported that the expressions of both NLRC5 and CIITA were highly induced after IFN-γ stimulation (
42). Recently, it has been demonstrated the regulatory role of NLRC5 in IFN-c through MHC class I-mediated CD8+ T cell activation, followed by the IFN-c–mediated upregulation of NLRC5 expression as a positive feedback loop for the promotion of MHC class I-dependent immune responses (
43).
NLRC3 expression has been shown in T lymphocytes and other immune cells. Its inhibitory role in T cell activation has been reported in response to stimulation with anti-CD28 and anti-CD3 antibodies (
37). NLRC3 interaction with target proteins leads to the weakening of the immune response in several important inflammatory pathways (
16). It is suggested that competition between NLRC3 and inflammatory components appears as a brake on the synthesis of pro-inflammatory cytokines and probably their secretion (
44). Zhang et al. demonstrated that NLRC3-knockout mice infected with herpes simplex virus (HSV) showed an increase in the innate immune response as compared to wild-type mice (
44). In addition, Gultekin et al. proposed that NLRC3 overexpression could negatively regulate inflammatory responses via the NF-κB signaling pathway and/or inflammasome complex formation (
16).
In another study, Shiau et al. found that NLRC3 mutation led to the activation of primitive macrophages associated with systemic inflammation, increased pro-inflammatory cytokines, and macrophage aggregation rather than their migration into the brain to form microglia (
45). Dysregulated innate immunity has been indicated to result in many inflammation-associated diseases. Thus, the growing recognition of the molecular mechanisms regulating negatively innate immunity appears to be useful in developing novel and more effective treatments to prevent inflammation-induced autoimmune diseases and cancer. Altogether, we would be interested in investigating other family members of NLRCs genes, which may be involved in the immunomodulatory properties of MSCs.
5.1. Conclusion
The effect of treatment with IFN-γ was led to increased expression of NLRC3 and NLRC5 genes in IFN-γ–treated WJ-MSCs. Therefore, it may be suggested as a proper source for cell therapy, especially in inflammatory conditions.